Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
Identifieur interne : 000212 ( Ncbi/Merge ); précédent : 000211; suivant : 000213Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
Auteurs : Ran D. Balicer [Israël] ; Michael Huerta [Israël] ; Nadav Davidovitch [Israël] ; Itamar Grotto [Israël]Source :
- Emerging Infectious Diseases [ 1080-6040 ] ; 2005.
Descripteurs français
- KwdFr :
- Acétamides (usage thérapeutique), Acétamides (économie), Adolescent, Adulte, Adulte d'âge moyen, Analyse coût-bénéfice, Antiviraux (usage thérapeutique), Antiviraux (économie), Enfant, Enfant d'âge préscolaire, Flambées de maladies (économie), Grippe humaine (traitement médicamenteux), Grippe humaine (économie), Grippe humaine (épidémiologie), Humains, Israël (épidémiologie), Modèles biologiques, Modèles économiques, Nourrisson, Organisation mondiale de la santé, Oséltamivir, Sujet âgé.
- MESH :
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Acétamides, Antiviraux.
- économie : Acétamides, Antiviraux, Flambées de maladies, Grippe humaine.
- épidémiologie : Grippe humaine, Israël.
- Adolescent, Adulte, Adulte d'âge moyen, Analyse coût-bénéfice, Enfant, Enfant d'âge préscolaire, Humains, Modèles biologiques, Modèles économiques, Nourrisson, Organisation mondiale de la santé, Oséltamivir, Sujet âgé.
- Wicri :
- geographic : Israël.
English descriptors
- KwdEn :
- Acetamides (economics), Acetamides (therapeutic use), Adolescent, Adult, Aged, Antiviral Agents (economics), Antiviral Agents (therapeutic use), Child, Child, Preschool, Cost-Benefit Analysis, Disease Outbreaks (economics), Humans, Infant, Influenza, Human (drug therapy), Influenza, Human (economics), Influenza, Human (epidemiology), Israel (epidemiology), Middle Aged, Models, Biological, Models, Economic, Oseltamivir, World Health Organization.
- MESH :
- chemical , economics : Acetamides, Antiviral Agents.
- chemical , therapeutic use : Acetamides, Antiviral Agents.
- geographic , epidemiology : Israel.
- drug therapy : Influenza, Human.
- economics : Disease Outbreaks, Influenza, Human.
- epidemiology : Influenza, Human.
- Adolescent, Adult, Aged, Child, Child, Preschool, Cost-Benefit Analysis, Humans, Infant, Middle Aged, Models, Biological, Models, Economic, Oseltamivir, World Health Organization.
Abstract
We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.
Url:
DOI: 10.3201/eid1108.041156
PubMed: 16102319
PubMed Central: 3320484
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000444
- to stream Pmc, to step Curation: 000444
- to stream Pmc, to step Checkpoint: 000F06
- to stream PubMed, to step Corpus: 001E42
- to stream PubMed, to step Curation: 001E42
- to stream PubMed, to step Checkpoint: 001C56
Links to Exploration step
PMC:3320484Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-Benefit of Stockpiling Drugs for Influenza Pandemic</title><author><name sortKey="Balicer, Ran D" sort="Balicer, Ran D" uniqKey="Balicer R" first="Ran D." last="Balicer">Ran D. Balicer</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2">Ben-Gurion University of the Negev, Be'er-Sheva, Israel</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ben-Gurion University of the Negev, Be'er-Sheva</wicri:regionArea><wicri:noRegion>Be'er-Sheva</wicri:noRegion></affiliation></author><author><name sortKey="Huerta, Michael" sort="Huerta, Michael" uniqKey="Huerta M" first="Michael" last="Huerta">Michael Huerta</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Davidovitch, Nadav" sort="Davidovitch, Nadav" uniqKey="Davidovitch N" first="Nadav" last="Davidovitch">Nadav Davidovitch</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2">Ben-Gurion University of the Negev, Be'er-Sheva, Israel</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ben-Gurion University of the Negev, Be'er-Sheva</wicri:regionArea><wicri:noRegion>Be'er-Sheva</wicri:noRegion></affiliation></author><author><name sortKey="Grotto, Itamar" sort="Grotto, Itamar" uniqKey="Grotto I" first="Itamar" last="Grotto">Itamar Grotto</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2">Ben-Gurion University of the Negev, Be'er-Sheva, Israel</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ben-Gurion University of the Negev, Be'er-Sheva</wicri:regionArea><wicri:noRegion>Be'er-Sheva</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">16102319</idno><idno type="pmc">3320484</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320484</idno><idno type="RBID">PMC:3320484</idno><idno type="doi">10.3201/eid1108.041156</idno><date when="2005">2005</date><idno type="wicri:Area/Pmc/Corpus">000444</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000444</idno><idno type="wicri:Area/Pmc/Curation">000444</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000444</idno><idno type="wicri:Area/Pmc/Checkpoint">000F06</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000F06</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16102319</idno><idno type="wicri:Area/PubMed/Corpus">001E42</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E42</idno><idno type="wicri:Area/PubMed/Curation">001E42</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001E42</idno><idno type="wicri:Area/PubMed/Checkpoint">001C56</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001C56</idno><idno type="wicri:Area/Ncbi/Merge">000212</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Cost-Benefit of Stockpiling Drugs for Influenza Pandemic</title><author><name sortKey="Balicer, Ran D" sort="Balicer, Ran D" uniqKey="Balicer R" first="Ran D." last="Balicer">Ran D. Balicer</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2">Ben-Gurion University of the Negev, Be'er-Sheva, Israel</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ben-Gurion University of the Negev, Be'er-Sheva</wicri:regionArea><wicri:noRegion>Be'er-Sheva</wicri:noRegion></affiliation></author><author><name sortKey="Huerta, Michael" sort="Huerta, Michael" uniqKey="Huerta M" first="Michael" last="Huerta">Michael Huerta</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Davidovitch, Nadav" sort="Davidovitch, Nadav" uniqKey="Davidovitch N" first="Nadav" last="Davidovitch">Nadav Davidovitch</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2">Ben-Gurion University of the Negev, Be'er-Sheva, Israel</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ben-Gurion University of the Negev, Be'er-Sheva</wicri:regionArea><wicri:noRegion>Be'er-Sheva</wicri:noRegion></affiliation></author><author><name sortKey="Grotto, Itamar" sort="Grotto, Itamar" uniqKey="Grotto I" first="Itamar" last="Grotto">Itamar Grotto</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2">Ben-Gurion University of the Negev, Be'er-Sheva, Israel</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ben-Gurion University of the Negev, Be'er-Sheva</wicri:regionArea><wicri:noRegion>Be'er-Sheva</wicri:noRegion></affiliation></author></analytic><series><title level="j">Emerging Infectious Diseases</title><idno type="ISSN">1080-6040</idno><idno type="eISSN">1080-6059</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (economics)</term><term>Acetamides (therapeutic use)</term><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Antiviral Agents (economics)</term><term>Antiviral Agents (therapeutic use)</term><term>Child</term><term>Child, Preschool</term><term>Cost-Benefit Analysis</term><term>Disease Outbreaks (economics)</term><term>Humans</term><term>Infant</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (epidemiology)</term><term>Israel (epidemiology)</term><term>Middle Aged</term><term>Models, Biological</term><term>Models, Economic</term><term>Oseltamivir</term><term>World Health Organization</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acétamides (usage thérapeutique)</term><term>Acétamides (économie)</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Antiviraux (usage thérapeutique)</term><term>Antiviraux (économie)</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Flambées de maladies (économie)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (économie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Israël (épidémiologie)</term><term>Modèles biologiques</term><term>Modèles économiques</term><term>Nourrisson</term><term>Organisation mondiale de la santé</term><term>Oséltamivir</term><term>Sujet âgé</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Acetamides</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetamides</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Israel</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acétamides</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Acétamides</term><term>Antiviraux</term><term>Flambées de maladies</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term><term>Israël</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Child</term><term>Child, Preschool</term><term>Cost-Benefit Analysis</term><term>Humans</term><term>Infant</term><term>Middle Aged</term><term>Models, Biological</term><term>Models, Economic</term><term>Oseltamivir</term><term>World Health Organization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Humains</term><term>Modèles biologiques</term><term>Modèles économiques</term><term>Nourrisson</term><term>Organisation mondiale de la santé</term><term>Oséltamivir</term><term>Sujet âgé</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Israël</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><double pmid="16102319"><pmc><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-Benefit of Stockpiling Drugs for Influenza Pandemic</title><author><name sortKey="Balicer, Ran D" sort="Balicer, Ran D" uniqKey="Balicer R" first="Ran D." last="Balicer">Ran D. Balicer</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2">Ben-Gurion University of the Negev, Be'er-Sheva, Israel</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ben-Gurion University of the Negev, Be'er-Sheva</wicri:regionArea><wicri:noRegion>Be'er-Sheva</wicri:noRegion></affiliation></author><author><name sortKey="Huerta, Michael" sort="Huerta, Michael" uniqKey="Huerta M" first="Michael" last="Huerta">Michael Huerta</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Davidovitch, Nadav" sort="Davidovitch, Nadav" uniqKey="Davidovitch N" first="Nadav" last="Davidovitch">Nadav Davidovitch</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2">Ben-Gurion University of the Negev, Be'er-Sheva, Israel</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ben-Gurion University of the Negev, Be'er-Sheva</wicri:regionArea><wicri:noRegion>Be'er-Sheva</wicri:noRegion></affiliation></author><author><name sortKey="Grotto, Itamar" sort="Grotto, Itamar" uniqKey="Grotto I" first="Itamar" last="Grotto">Itamar Grotto</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2">Ben-Gurion University of the Negev, Be'er-Sheva, Israel</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ben-Gurion University of the Negev, Be'er-Sheva</wicri:regionArea><wicri:noRegion>Be'er-Sheva</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">16102319</idno><idno type="pmc">3320484</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320484</idno><idno type="RBID">PMC:3320484</idno><idno type="doi">10.3201/eid1108.041156</idno><date when="2005">2005</date><idno type="wicri:Area/Pmc/Corpus">000444</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000444</idno><idno type="wicri:Area/Pmc/Curation">000444</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000444</idno><idno type="wicri:Area/Pmc/Checkpoint">000F06</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000F06</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Cost-Benefit of Stockpiling Drugs for Influenza Pandemic</title><author><name sortKey="Balicer, Ran D" sort="Balicer, Ran D" uniqKey="Balicer R" first="Ran D." last="Balicer">Ran D. Balicer</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2">Ben-Gurion University of the Negev, Be'er-Sheva, Israel</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ben-Gurion University of the Negev, Be'er-Sheva</wicri:regionArea><wicri:noRegion>Be'er-Sheva</wicri:noRegion></affiliation></author><author><name sortKey="Huerta, Michael" sort="Huerta, Michael" uniqKey="Huerta M" first="Michael" last="Huerta">Michael Huerta</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Davidovitch, Nadav" sort="Davidovitch, Nadav" uniqKey="Davidovitch N" first="Nadav" last="Davidovitch">Nadav Davidovitch</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2">Ben-Gurion University of the Negev, Be'er-Sheva, Israel</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ben-Gurion University of the Negev, Be'er-Sheva</wicri:regionArea><wicri:noRegion>Be'er-Sheva</wicri:noRegion></affiliation></author><author><name sortKey="Grotto, Itamar" sort="Grotto, Itamar" uniqKey="Grotto I" first="Itamar" last="Grotto">Itamar Grotto</name><affiliation wicri:level="1"><nlm:aff id="aff1">Ministry of Health, Jerusalem, Israel;</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2">Ben-Gurion University of the Negev, Be'er-Sheva, Israel</nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Ben-Gurion University of the Negev, Be'er-Sheva</wicri:regionArea><wicri:noRegion>Be'er-Sheva</wicri:noRegion></affiliation></author></analytic><series><title level="j">Emerging Infectious Diseases</title><idno type="ISSN">1080-6040</idno><idno type="eISSN">1080-6059</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI></pmc><pubmed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-benefit of stockpiling drugs for influenza pandemic.</title><author><name sortKey="Balicer, Ran D" sort="Balicer, Ran D" uniqKey="Balicer R" first="Ran D" last="Balicer">Ran D. Balicer</name><affiliation wicri:level="1"><nlm:affiliation>Ministry of Health, Jerusalem, Israel. rbalicer@netvision.net.il</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Huerta, Michael" sort="Huerta, Michael" uniqKey="Huerta M" first="Michael" last="Huerta">Michael Huerta</name></author><author><name sortKey="Davidovitch, Nadav" sort="Davidovitch, Nadav" uniqKey="Davidovitch N" first="Nadav" last="Davidovitch">Nadav Davidovitch</name></author><author><name sortKey="Grotto, Itamar" sort="Grotto, Itamar" uniqKey="Grotto I" first="Itamar" last="Grotto">Itamar Grotto</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16102319</idno><idno type="pmid">16102319</idno><idno type="doi">10.3201/eid1108.041156</idno><idno type="wicri:Area/PubMed/Corpus">001E42</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E42</idno><idno type="wicri:Area/PubMed/Curation">001E42</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001E42</idno><idno type="wicri:Area/PubMed/Checkpoint">001C56</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001C56</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cost-benefit of stockpiling drugs for influenza pandemic.</title><author><name sortKey="Balicer, Ran D" sort="Balicer, Ran D" uniqKey="Balicer R" first="Ran D" last="Balicer">Ran D. Balicer</name><affiliation wicri:level="1"><nlm:affiliation>Ministry of Health, Jerusalem, Israel. rbalicer@netvision.net.il</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Huerta, Michael" sort="Huerta, Michael" uniqKey="Huerta M" first="Michael" last="Huerta">Michael Huerta</name></author><author><name sortKey="Davidovitch, Nadav" sort="Davidovitch, Nadav" uniqKey="Davidovitch N" first="Nadav" last="Davidovitch">Nadav Davidovitch</name></author><author><name sortKey="Grotto, Itamar" sort="Grotto, Itamar" uniqKey="Grotto I" first="Itamar" last="Grotto">Itamar Grotto</name></author></analytic><series><title level="j">Emerging infectious diseases</title><idno type="ISSN">1080-6040</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (economics)</term><term>Acetamides (therapeutic use)</term><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Antiviral Agents (economics)</term><term>Antiviral Agents (therapeutic use)</term><term>Child</term><term>Child, Preschool</term><term>Cost-Benefit Analysis</term><term>Disease Outbreaks (economics)</term><term>Humans</term><term>Infant</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (epidemiology)</term><term>Israel (epidemiology)</term><term>Middle Aged</term><term>Models, Biological</term><term>Models, Economic</term><term>Oseltamivir</term><term>World Health Organization</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acétamides (usage thérapeutique)</term><term>Acétamides (économie)</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Antiviraux (usage thérapeutique)</term><term>Antiviraux (économie)</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Flambées de maladies (économie)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (économie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Israël (épidémiologie)</term><term>Modèles biologiques</term><term>Modèles économiques</term><term>Nourrisson</term><term>Organisation mondiale de la santé</term><term>Oséltamivir</term><term>Sujet âgé</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Acetamides</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetamides</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Israel</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acétamides</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Acétamides</term><term>Antiviraux</term><term>Flambées de maladies</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term><term>Israël</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Child</term><term>Child, Preschool</term><term>Cost-Benefit Analysis</term><term>Humans</term><term>Infant</term><term>Middle Aged</term><term>Models, Biological</term><term>Models, Economic</term><term>Oseltamivir</term><term>World Health Organization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Humains</term><term>Modèles biologiques</term><term>Modèles économiques</term><term>Nourrisson</term><term>Organisation mondiale de la santé</term><term>Oséltamivir</term><term>Sujet âgé</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Israël</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.</div></front></TEI></pubmed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000212 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000212 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:3320484
|texte= Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:16102319" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |